Further efficacy and safety data for maintenance upadacitinib in ulcerative colitis
- PMID: 37683685
- DOI: 10.1016/S2468-1253(23)00271-6
Further efficacy and safety data for maintenance upadacitinib in ulcerative colitis
Conflict of interest statement
RA has served as a speaker, or consultant, or received research grants from AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion Healthcare, DrFalk Pharma, Galapagos, Gilead, InDex Pharmaceuticals, Janssen-Cilag, Lilly, MSD Sharp & Dohme, Roche Pharma, Samsung Bioepsis, and Takeda Pharma. MN reports research grants or personal fees from AbbVie, MSD, Takeda, Boehringer, Roche, Pfizer, Janssen, Pentax, and PPM.
Comment on
-
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.Lancet Gastroenterol Hepatol. 2023 Nov;8(11):976-989. doi: 10.1016/S2468-1253(23)00208-X. Epub 2023 Sep 9. Lancet Gastroenterol Hepatol. 2023. PMID: 37683686 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
